{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:32:14Z","timestamp":1791613934136,"version":"4.3.4"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2018.8006","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T19:02:03Z","timestamp":1549652523000},"page":"e188006","source":"Crossref","is-referenced-by-count":305,"title":["Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer"],"prefix":"10.1001","volume":"2","author":[{"given":"Amar U.","family":"Kishan","sequence":"first","affiliation":[{"name":"Department of Urology, University of California, Los Angeles"},{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Katz","sequence":"additional","affiliation":[{"name":"Flushing Radiation Oncology Services, Flushing, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A.","family":"Mantz","sequence":"additional","affiliation":[{"name":"21st Century Oncology, Fort Myers, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Aghdam","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-I","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving D.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Division of Genesis Healthcare Partners Inc, CyberKnife Centers of San Diego Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Meier","sequence":"additional","affiliation":[{"name":"Swedish Radiosurgery Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Andrew","family":"Loblaw","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong T.","family":"Pham","sequence":"additional","affiliation":[{"name":"Section of Radiation Oncology, Virginia Mason Medical Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narek","family":"Shaverdian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"},{"name":"Now with Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Bagshaw","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Prionas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Buyyounouski","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Linson","sequence":"additional","affiliation":[{"name":"Scripps Health, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Hong","sequence":"additional","affiliation":[{"name":"Virginia Hospital Center, Arlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Kupelian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"issue":"9856","key":"zoi180332r1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","article-title":"Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions.","volume":"380","author":"Soerjomataram","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"zoi180332r3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma.","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"zoi180332r4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"zoi180332r5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer.","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi180332r6","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer.","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi180332r7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.semradonc.2017.02.006","article-title":"Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer.","volume":"27","author":"Kishan","year":"2017","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"zoi180332r8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"issue":"18","key":"zoi180332r9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer.","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi180332r10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cncr.v122.3","article-title":"Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.","volume":"122","author":"Laviana","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"zoi180332r11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijrobp.2016.11.007","article-title":"Exploring value from the patient\u2019s perspective between modern radiation therapy modalities for localized prostate cancer.","volume":"97","author":"Shaverdian","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"zoi180332r12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1200\/JCO.2014.55.2380","article-title":"Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis.","volume":"32","author":"D\u2019Amico","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi180332r13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","article-title":"Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi180332r14","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/cncr.v122.16","article-title":"Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.","volume":"122","author":"Halpern","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"zoi180332r16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi180332r17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi180332r18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"zoi180332r19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fonc.2014.00279","article-title":"A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up.","volume":"4","author":"Mantz","year":"2014","journal-title":"Front Oncol"},{"issue":"2","key":"zoi180332r20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints.","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"zoi180332r21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes.","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"zoi180332r22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials.","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"issue":"15","key":"zoi180332r23","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial.","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"zoi180332r25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fonc.2014.00321","article-title":"Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations.","volume":"4","author":"Fuller","year":"2014","journal-title":"Front Oncol"},{"key":"zoi180332r26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fonc.2017.00157","article-title":"Prostate-specific antigen 5 years following stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: an ablative procedure?","volume":"7","author":"Kataria","year":"2017","journal-title":"Front Oncol"},{"issue":"6","key":"zoi180332r27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"zoi180332r28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"zoi180332r33","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","article-title":"Choice and interpretation of statistical tests used when competing risks are present.","volume":"26","author":"Dignam","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi180332r35","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial.","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi180332r36","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ijrobp.2016.06.026","article-title":"Initial report of NRG Oncology\/RTOG 0232: a phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma.","volume":"96","author":"Prestidge","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi180332r37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijrobp.2017.09.050","article-title":"Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes.","volume":"100","author":"Frank","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi180332r38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.radonc.2018.03.022","article-title":"High dose rate brachytherapy for prostate cancer: a prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.","volume":"127","author":"Nagore","year":"2018","journal-title":"Radiother Oncol"},{"issue":"2","key":"zoi180332r39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi180332r40","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi180332r41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"zoi180332r15","first-page":"D1","author":"Kolata","year":"2017"},{"key":"zoi180332r42","author":"Widmark","year":"2018"},{"key":"zoi180332r2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version I. https:\/\/www2.tri-kobe.org\/nccn\/guideline\/urological\/english\/prostate.pdf. Accessed November 30, 2015."},{"key":"zoi180332r24","unstructured":"ClinicalTrials.gov. Hypo-fractionated stereotactic body radiotherapy for localized prostate cancer. ClinicalTrials.gov Identifier: NCT01059513. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01059513. Updated April 30, 2018. Accessed January 7, 2019."},{"key":"zoi180332r29","unstructured":"National Cancer Institute, National Institutes of Health. Common Toxicity Criteria, version 2.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf. Published April 30, 1999. Accessed January 6, 2019."},{"key":"zoi180332r30","unstructured":"National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events, version 3.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Published August 9, 2006. Accessed January 6, 2019."},{"key":"zoi180332r31","unstructured":"National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published May 28, 2009. Accessed January 6, 2019."},{"key":"zoi180332r32","unstructured":"Radiation Therapy Oncology Group Foundation. Cooperative group common toxicity criteria. https:\/\/www.rtog.org\/ResearchAssociates\/AdverseEventReporting\/CooperativeGroupCommonToxicityCriteria.aspx. Accessed January 6, 2019."},{"key":"zoi180332r34","unstructured":"The R Foundation. The R project for statistical computing. https:\/\/www.R-project.org\/. Accessed July 7, 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2723641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T18:49:09Z","timestamp":1550083749000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2018.8006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.8006","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]}}}